Interferon alfa-2a.
Interferon alfa-2a shows both antiviral and antitumoral activity, but its role in the treatment of many conditions remains controversial. It is, however, the treatment of choice for chronic, active hepatitis B, chronic hepatitis C and AIDS-related Kaposi's sarcoma, and is also effective in metastatic renal carcinoma and chronic myelogenous leukaemia. Optimal dose regimens are unclear, and further randomized trials are needed.
Williams
C D
CD
Department of Haematology, University College London Hospitals.
Linch
D C
DC
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006509:Hepatitis B / Q000628:therapy; D006526:Hepatitis C / Q000628:therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy; D007943:Leukemia, Hairy Cell / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D009101:Multiple Myeloma / Q000628:therapy; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000628:therapy
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins